Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AYTU BIOPHARMA, INCAYTU · Entity 7560 | Chief Financial Officer | March 16, 2017 | March 17, 2017 |
| Aclarion, Inc.ACON · Entity 8157 | CFO | August 14, 2026 | August 18, 2026 |
| Charlotte's Web Holdings, Inc.CWBHF · Entity 2770 | Chief Financial Officer | June 17, 2022 | June 21, 2022 |
| CytoDyn Inc.CYDY · Entity 5856 | Director | June 18, 2019 | June 20, 2019 |
| NewAge, Inc.NBEV · Entity 129046 | Chief Financial Officer | July 02, 2021 | July 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AYTU BIOPHARMA, INC
Report date March 16, 2017 · Filed March 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2015-11-11 | Direct | 0 |
Reported balance
After 2017-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-16 · Disposition to issuer · Disposed 20,834 · Balance 0 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2: These options are 100% vested. |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.23 · Expires 2026-07-07 | Direct | 0 |
Reported balance
After 2017-03-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates. |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2015-11-11 | Direct | 20,834 |
Reported balance
After 2017-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-16 · Grant · Acquired 20,834 · Balance 20,834 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2: These options are 100% vested. |
| Employee Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2026-07-07 | Direct | 25,000 |
Reported balance
After 2017-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-03-16 · Grant · Acquired 25,000 · Balance 25,000 F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates. |
| Common StockSEC Table I · non-derivative | Direct | 340,231 |
Reported balance
Holding disclosure · report date 2017-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 340,231 F1: Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2021-11-02 | Direct | 0 |
Reported balance
Holding disclosure · report date 2017-03-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations.
F2: These options are 100% vested.
F3: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates.
F4: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option.
Aclarion, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,000 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 10,000 · Balance 60,000 F1: The Reporting Person purchased common stock on the public market on 08-14-2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased common stock on the public market on 08-14-2026.
Charlotte's Web Holdings, Inc.
Report date June 17, 2022 · Filed June 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2032-06-17 | Direct | 1,200,000 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 1,200,000 · Balance 1,200,000 F1: The option agreement provides that the option becomes exercisable in 2 equal annual installments beginning on 6/18/2023. The option was granted on 6/17/2022 in connection with Mr. Gould's appointment as an officer of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option agreement provides that the option becomes exercisable in 2 equal annual installments beginning on 6/18/2023. The option was granted on 6/17/2022 in connection with Mr. Gould's appointment as an officer of the Company.
CytoDyn Inc.
Report date June 18, 2019 · Filed June 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2029-06-18 | Direct | 100,000 |
Reported balance
After 2019-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-18 · Grant · Acquired 100,000 · Balance 100,000 F1: The options will vest in four equal quarterly installments, commencing on September 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in four equal quarterly installments, commencing on September 1, 2019.
NewAge, Inc.
Report date July 02, 2021 · Filed July 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 331,255 |
Reported balance
After 2021-07-02 transaction · row 1
1 source rowRow 1 · 2021-07-02 · Tax withholding · Disposed 73,110 · Balance 331,255 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 12:30 UTC | Aclarion, Inc. ACON · Entity 8157 | PurchaseCommon Stock | 10,000 | $2.45 | $24,500.00 |
DisclosureSEC source: 0001683168-26-006545 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 F1 · shares: The Reporting Person purchased common stock on the public market on 08-14-2026. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 20:30 UTC | Aclarion, Inc. ACON · Entity 8157 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-004813 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares reported are restricted stock units ("RSUs") granted 6/11/2026 under the Company's equity incentive plan. Each RSU represents a contingent right to receive one share of ACON common stock. F2 · shares: 100% of the RSUs shall vest on 6/1/2027. Any outstanding and unvested RSUs will also accelerate and fully vest upon a change of control (as defined in the Company's equity incentive plan). Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 21:10 UTC | Aclarion, Inc. ACON · Entity 8157 | GrantStock Option (right to buy) · Derivative | 17,000 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001683168-25-006662 · ownership.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2035-09-02 F1 · derivative.exercise_date: The option will vest 25% on September 2, 2026. The remaining 75% will vest thereafter in 36 equal monthly installments over the following three years. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 18:09 UTC | Charlotte's Web Holdings, Inc. CWBHF · Entity 2770 | GrantStock Option (right to buy) · Derivative | 1,200,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001750155-22-000070 · wf-form4_165583494459513.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Common Shares · 1,200,000 shares Expires 2032-06-17 F1 · derivative.exercise_date: The option agreement provides that the option becomes exercisable in 2 equal annual installments beginning on 6/18/2023. The option was granted on 6/17/2022 in connection with Mr. Gould's appointment as an officer of the Company. Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 22:18 UTC | NewAge, Inc. NBEV · Entity 129046 | Tax withholdingCommon Stock | 73,110 | $2.24 | $163,766.40 |
DisclosureSEC source: 0001493152-21-016394 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,255 Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:23 UTC | NewAge, Inc. NBEV · Entity 129046 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001493152-21-005923 · ownership.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2024-03-10 F1 · derivative.exercise_date: Option vests on July 2, 2021. Read SEC document |
| January 05, 2021 Filed Jan 6, 2021 02:13 UTC | NewAge, Inc. NBEV · Entity 129046 | Tax withholdingCommon Stock | 26,507 | $2.63 | $69,713.41 |
DisclosureSEC source: 0001493152-21-000251 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,365 F1 · shares: In accordance with the 2016-2017 Long-Term Incentive Plan ("Plan") of NewAge, Inc. (the "Company"), the Reporting Person returned shares of the Company's common stock to the Company to pay the Reporting Person's withholding taxes due upon the vesting of restricted shares of common stock previously awarded to the Reporting Person under the Plan on July 1, 2019. Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 00:06 UTC | NewAge, Inc. NBEV · Entity 129046 | Tax withholdingCommon Stock | 9,564 | $3.16 | $30,222.24 |
DisclosureSEC source: 0001493152-20-023426 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,872 F1 · shares: In accordance with the 2019 Equity Incentive Plan ("Plan") of NewAge, Inc. (the "Company"), the Reporting Person returned shares of the Company's common stock to the Company to pay the Reporting Person's withholding taxes due upon the vesting of restricted shares of common stock previously awarded to the Reporting Person under the Plan on December 10, 2019. Read SEC document |
| October 22, 2020 Filed Oct 26, 2020 21:09 UTC | NewAge, Inc. NBEV · Entity 129046 | Tax withholdingCommon Stock | 9,564 | $2.72 | $26,014.08 |
DisclosureSEC source: 0001493152-20-019963 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,436 F1 · shares: In accordance with the 2019 Equity Incentive Plan ("Plan") of NewAge, Inc. (the "Company"), the Reporting Person returned shares of the Company's common stock to the Company to pay the Reporting Person's withholding taxes due upon the vesting of restricted shares of common stock previously awarded to the Reporting Person under the Plan on July 1, 2019. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 23:03 UTC | NewAge, Inc. NBEV · Entity 129046 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0001493152-19-019124 · ownership.xml · derivative · entry 2 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-10 F2 · derivative.exercise_date: The option vests as follows: 33% on December 10, 2020, 33% on December 10, 2021 and 34% on December 10, 2022. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 23:03 UTC | NewAge, Inc. NBEV · Entity 129046 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-019124 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 F1 · shares: On December 10, 2019, New Age Beverages Corporation (the "Company") issued 100,000 restricted shares of the Company's common stock ("Common Stock") to Mr. Gould. The Common Stock vests as follows: 33% on December 10, 2020, 33% on December 10, 2021 and 34% on December 10, 2022. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:20 UTC | NewAge, Inc. NBEV · Entity 129046 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001213900-19-012063 · ownership.xml · derivative · entry 3 Gould Gregory A · CIK 0001252905 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-07-01 F3 · derivative.exercise_date: On July 1, 2019, the Company issued to Mr. Gould an option (the "Option") to purchase 100,000 shares of the Company's Common Stock at a purchase price of $4.75, representing the closing price of the Common Stock on the date of grant. The Option was issued pursuant to the terms of his employment letter dated October 3, 2018 with the Company and vests as follows: 33% on December 15, 2019, 33% on December 15, 2020 and 34% on December 15, 2021. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:20 UTC | NewAge, Inc. NBEV · Entity 129046 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-012063 · ownership.xml · nonDerivative · entry 2 Gould Gregory A · CIK 0001252905 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 F2 · shares: On July 1, 2019, the Company issued 250,000 restricted shares of the Company's Common Stock to Mr. Gould. The Common Stock was issued pursuant to the terms of his employment letter dated October 3, 2018 with the Company and vests as follows: 33% on January 2, 2020, 33% on January 2, 2021 and 34% on January 2, 2022. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:20 UTC | NewAge, Inc. NBEV · Entity 129046 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-012063 · ownership.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F1 · shares: On July 1, 2019, New Age Beverages Corporation (the "Company") issued 100,000 restricted shares of the Company's common stock ("Common Stock") to Mr. Gould. The Common Stock was issued pursuant to the terms of his employment letter dated October 3, 2018 with the Company and vests as follows: 33% on October 22, 2019, 33% on October 22, 2020 and 34% on October 22, 2021. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 00:58 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0000899243-19-017505 · doc4.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments, commencing on September 1, 2019. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 11 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · derivative.exercise_date: The options vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 10 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 160,662 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 9 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,662 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 8 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 7 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2026-11-17 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 6 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 5 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 4 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2022-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 3 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2021-08-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · derivative · entry 2 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 16, 2018 23:32 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerCommon Stock | 19,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029192 · doc4.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 11 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). F3 · derivative.exercise_date: The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.80 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 10 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2023-02-15 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 160,662 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 9 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,662 Underlying: Common Stock · 160,662 shares Expires 2028-02-07 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | Not disclosed Strike: $0.57 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 8 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 7 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-11-17 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 6 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.98 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 5 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 25,000 | Not disclosed Strike: $1.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 4 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2022-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 3 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2021-08-08 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · derivative · entry 2 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-06-01 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 13:01 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantCommon Stock | 19,176 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-029257 · doc4.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,176 F1 · price: On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. ("Old CytoDyn") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) ("New CytoDyn") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the "Holding Company Reorganization"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock. F2 · price: In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance). Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 21:55 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0000899243-18-016229 · doc4.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000899243-18-004434 · doc4.xml · derivative · entry 2 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2023-06-01 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 23:00 UTC | CytoDyn Inc. CYDY · Entity 5856 | Disposition to issuerStock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0000899243-18-004434 · doc4.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2018-06-01 F1 · derivative.exercise_date: Such options were fully vested and exercisable as of the date of the reported transactions. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:06 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 160,662 | Not disclosed Strike: $0.56 | Not disclosed |
DisclosureSEC source: 0000899243-18-003462 · doc4.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,662 Underlying: Common Stock · 160,662 shares Expires 2028-02-07 F1 · price: On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:45 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0000899243-17-015349 · doc4.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:25 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 25,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000297 · doc4_4625.xml · derivative · entry 6 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:25 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | GrantEmployee Stock Option Grant · Derivative | 20,834 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001638599-17-000297 · doc4_4625.xml · derivative · entry 5 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,834 Underlying: Common Stock · 20,834 shares Expires 2015-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: These options are 100% vested. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:25 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 25,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000297 · doc4_4625.xml · derivative · entry 4 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-07-07 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F3 · derivative.exercise_date: 33.3% vests on the one year, two year and three year anniversary of the date of grant, subject to the Grantee's service as an employee on such dates. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 20:25 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Disposition to issuerEmployee Stock Option Grant · Derivative | 20,834 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001638599-17-000297 · doc4_4625.xml · derivative · entry 3 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,834 shares Expires 2015-11-11 F4 · kind: These four transactions involved an amendment of the exercise price of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. F2 · derivative.exercise_date: These options are 100% vested. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 00:33 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionWarrant to Purchase Common Stock · Derivative | 66,666 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001638599-17-000235 · doc4_4576.xml · derivative · entry 2 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,666 shares Expires 2021-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 00:33 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | Exercise / conversionCommon Stock | 66,666 | $0.75 | $49,999.50 |
DisclosureSEC source: 0001638599-17-000235 · doc4_4576.xml · nonDerivative · entry 1 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Of these shares, 165,000 shares are restricted shares that vest on July 7, 2026, subject to earlier vesting in certain situations. Read SEC document |
| November 17, 2016 Filed Nov 21, 2016 21:48 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.68 | $0.00 |
DisclosureSEC source: 0000899243-16-034017 · doc4.xml · derivative · entry 1 Gould Gregory A · CIK 0001252905 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-11-17 F1 · derivative.exercise_date: The option vests 25% on the date of grant and the remaining 75% in equal monthly installments over the next year. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 20:58 UTC | AYTU BIOPHARMA, INC AYTU · Entity 7560 | PurchaseWarrant to Purchase Common Stock · Derivative | 66,666 | Not disclosed Strike: $1.86 | Not disclosed |
DisclosureSEC source: 0001638599-16-001508 · doc4_4277.xml · derivative · entry 2 Gould Gregory A · CIK 0001252905 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,666 shares Expires 2021-11-02 F1 · price: The shares of stock and warrants were purchased at a purchase price per unit of $1.50. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.